LOGIN  |  REGISTER
Chimerix
Astria Therapeutics

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

October 14, 2025 | Last Trade: US$0.90 0.0052 0.58

GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET).

LD Micro Main Event XIX Conference
Presentation Date: Tuesday, October 21, 2025
Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)
Webcast: Click here

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro representative or email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

This press release was published by a CLEAR® Verified individual.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page